obesity-995x60.png
FEATURED ARTICLES
My SCOPE Groundhog Day Experience
From feasibility inefficiencies to overdesigned trials and overloaded investigative sites, the conversations at SCOPE were thoughtful and candid. The problem isn’t ignorance. It’s execution. Until simplification shows up in shorter timelines, leaner protocols, and measurable relief for sites, we may continue gathering each year to discuss the same issues — with the same data.
-
The Next Competitive Advantage In Clinical Trials Is Execution Intelligence
AI fails in clinical trials when decision-making is messy. To win, sponsors must fix their "execution blind spot" by structuring how work happens, letting AI turn hidden patterns into strategy.
-
How The FDA Is Helping To Operationalize Patient Voice In Trials
The FDA encourages patient experience data in drug labeling but often excludes it for low rigor. New guidelines should help sponsors meet strict methodological standards.
-
These Four Things Are Helping Minovia Therapeutics' Rare Disease Trials
Minovia Therapeutics shares the importance of careful site selection, specialized operational expertise, multidisciplinary collaboration, and innovative trial design as it prepares for pivotal this year.